Xoma Royalty CORP 8-K filings

XOMA Corporation is set to receive $8.1 million following Day One Biopharmaceuticals' sale of a priority review voucher.

XOMA Corporation successfully held its 2024 Annual Meeting of Stockholders, electing all director nominees and ratifying the selection of Deloitte & Touche LLP as independent auditor.

XOMA Corporation announced its first quarter 2024 financial results, showcasing revenue growth, strategic acquisitions, and key milestone achievements.

XOMA Corporation has acquired royalty and milestone interests in three women's health assets, including XACIATO, Ovaprene, and Sildenafil Cream, for an upfront payment of $22 million.

XOMA Corporation has secured a $9 million milestone payment due to the FDA's approval of Day One Biopharmaceuticals' OJEMDA for pediatric low-grade glioma treatment.

XOMA Corporation has finalized its acquisition of Kinnate Biopharma, completing a tender offer and subsequent merger on April 3, 2024.

XOMA Corporation announced its fourth quarter and full year 2023 financial results, highlighting a significant increase in cash position and strategic acquisitions.

XOMA Corporation has agreed to acquire Kinnate Biopharma for a base cash price of $2.3352 per share, an additional cash amount of up to $0.2527 per share, and a contingent value right.

XOMA Corporation has appointed Owen Hughes as its permanent CEO, increasing his base salary and bonus potential, and granted him performance-based stock units.